Amylin Speculation Intensifies: Byetta LAR May Be Delayed
This article was originally published in The Pink Sheet Daily
Executive Summary
Comparability studies could mean filing is impossible for first half of 2009, Amylin says.
You may also be interested in...
Bristol/ImClone Pull, Will Resubmit, Erbitux sBLA For Lung Cancer
ImClone Systems and Bristol-Myers Squibb are pulling a supplemental BLA for Erbitux (cetuximab) to treat non-small cell lung cancer, saying they plan to resubmit the application as soon as possible after answering manufacturing questions posed by FDA
Bristol/ImClone Pull, Will Resubmit, Erbitux sBLA For Lung Cancer
ImClone Systems and Bristol-Myers Squibb are pulling a supplemental BLA for Erbitux (cetuximab) to treat non-small cell lung cancer, saying they plan to resubmit the application as soon as possible after answering manufacturing questions posed by FDA
Groundhog Day For Byetta, GLP-1 Class: Is Regulatory Winter Nearly Over?
Sponsors of GLP-1 diabetes therapies and their investors are eagerly awaiting spring for greater clarity about the prospects of the antidiabetic class